# A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer

> **NCT06682247** · — · NOT_YET_RECRUITING · sponsor: **Feng Wang** · enrollment: 200 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors

## Key facts

- **NCT ID:** NCT06682247
- **Lead sponsor:** Feng Wang
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06682247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06682247, "A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06682247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*